Multidentate terephthalamidate and hydroxypyridonate ligands: Towards new orally active chelators

Hemoglobin

Volumn 35, Issue 3, 2011, Pages 276-290

  Abergel, Rebecca J ^a   Raymond, Kenneth N ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Actinide contamination; Chelating agents; Chelation therapy; Hydroxypyridonate ligands; Iron overload; Terephthalamidate ligands

Indexed keywords

ACTINIDE; AMERICIUM 241; CHELATING AGENT; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON 59; LINEAR HEXADENTATE LIGAND; LINEAR TETRADENTATE LIGAND; PENTETIC ACID; PLUTONIUM 238; SIDEROPHORE; TRANSFERRIN; TRIPODAL HEXADENTATE LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; BINDING AFFINITY; CHELATION THERAPY; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG EXCRETION; DRUG SELECTIVITY; FEMALE; IN VIVO STUDY; IRON OVERLOAD; MOUSE; NONHUMAN; RADIOACTIVE CONTAMINATION;

ACTINOID SERIES ELEMENTS; ANIMALS; BIOLOGICAL AVAILABILITY; CARBOXYLIC ACIDS; CHELATING AGENTS; DRUG EVALUATION, PRECLINICAL; FEMALE; IRON CHELATING AGENTS; LIGANDS; MICE; PHTHALIMIDES; PYRIDINES; RADIOACTIVE TRACERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957522059     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.560771     Document Type: Conference Paper

References (27)

1. Andrews NC. Disorders of iron metabolism. N Eng J Med. 1999;341(26): 1986-1995 (Pubitemid 30010408)
2. Durbin PW, Lauriston S. Taylor lecture: The quest for therapeutic actinide chelators. Health Phys. 2008;95(5): 465-492
3. Scott LE, Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev. 2009;109: 4885-4910
4. Hershko C. Oral iron chelators: new opportunities and new dilemmas. Haematologica. 2006;91(10): 1307-1312 (Pubitemid 44569802)
5. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2005;(4): CD004450 (Review).
6. Durbin PW. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, Eds. The Chemistry of the Actinide and Transactinide Elements. Amsterdam: Springer Verlag. 2006: 3339-3440
7. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007;(3): CD004849 (Review).
8. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9): 3436-3441
9. Porter JB. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today (Barc).2006;42(10): 623-637 (Pubitemid 44901638)
10. Kontoghiorghes GJ. Response to the Letter to the Editor. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6): 608-615
11. Hider RC, Zhou T. The design of orally active iron chelators. Ann NY Acad Sci. 2005;1054: 141-154 (Pubitemid 43031019)
12. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57(4): 547-583 (Pubitemid 43036441)
13. Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C. Irc011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. Blood. 1997;90(10): 4180-4187 (Pubitemid 27484074)
14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3): 3-26 (Pubitemid 33653411)
15. Abergel RJ, Raymond KN. Synthesis and thermodynamic evaluation of mixed hexadentate linear iron chelators containing hydroxypyridinone and terephthalamide units. Inorg Chem. 2006;45(9): 3622-3631
16. Abergel RJ, Raymond KN. Terephthalamide-containing ligands: fast removal of iron from transferrin. J Biol Inorg Chem. 2008;13(2): 229-240
17. Jurchen KMC, Raymond KN. A bidentate terephthalamide ligand, tammeg, as an entry into terephthalamide-containing therapeutic iron chelating agents. Inorg Chem. 2006;45(6): 2438-2447
18. Jurchen KMC, Raymond KN. Terephtalamide-containing analogs of tren-me-3,2-hopo. Inorg Chem. 2006;45(3): 1078-1090
19. Abergel RJ, Durbin PW, Kullgren B, et al. Biomimetic actinide chelators: An update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).Health Phys. 2010;99(3): 401-407
20. Durbin PW, Jeung N, Kullgren B, Clemons GK. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys. 1992;63(4): 427-442
21. Durbin PW, Kullgren B, Xu J, Raymond KN. In vivo chelation of Am(III), Pu(IV), Np(V), and U(VI) in mice by TREN(Me-3,2-HOPO).Radiat Prot Dosim. 1994; 53(1-4): 305-309 (Pubitemid 24239683)
22. Durbin PW, Kullgren B, Xu J, Raymond KN. Multidentate hydroxypyridonate ligands for Pu(IV) chelation in vivo: Comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. Int J Rad Biol. 2000;76(2): 199-214 (Pubitemid 30093467)
23. Raymond KN, Telford JR. Siderophore-mediated iron transport in microbes. In: Kessissoglou DP, Ed. Bioinorganic Chemistry An Inorganic Perspective of Life. Dordrecht: Kluwer Academic Publishers. 1995: 25-37
24. Evers A, Hancock RD, Martell AE, Motekaitis RJ. Metal-ion recognition in ligands with negatively charged oxygen donor groups-complexation of Fe(III), Ga(III), In(III), Al(III), and other highly charged metal-ions. Inorg Chem. 1989;28(11): 2189-2195
25. Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-bis(2- hydroxyphenyl)-1,2,4-triazol-1-yl]- benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int Ed. 1999;38(17): 2568-2570
26. Ma R, Reibenspies JJ, Martell AE. Stabilities of 1,2-diethyl-3-hydroxy-4- pyridinone chelates of divalent and trivalent metal-ions. Inorg Chim Acta. 1994;223(1-2): 21-29
27. Mack C. Essential of Statistics For Scientists and Technologists. New York: Plenum Press, 1967